Trial Profile

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary) ; Antipsoriatics
Indications Plaque psoriasis
Focus Therapeutic Use
Acronyms Complete-PS
Sponsors Abbott Laboratories; AbbVie

Most Recent Events

14 Mar 2022 Results compare real-world effectiveness of adalimumab versus topical/traditional systemic agents for management of moderate to severe plaque psoriasis, published in the Dermatology and Therapy
11 Jul 2018 Status changed from active, no longer recruiting to completed.
17 Jun 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com